HomeAI · summaries
Storia in 2 fonti
India's CDMO industry set for global shift as pharma diversifies beyond China: Sai Life Sciences
Indian contract manufacturers are poised for significant growth as global pharmaceutical giants diversify away from China. Companies like Sai Life Sciences are investing heavily in capacity, anticipating a surge in demand. While regulatory processes mean benefits will be gradual, this supply-chain realignment presents a landmark opportunity for India's CDMO sector, with major players already strengthening partnerships.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
thehindubusinessline.com
India pharma sector shifts focus to biosimilars, biologics and high-value growth
India pharma sector moves beyond generics to biosimilars, biologics and AI-driven manufacturing, strengthening exports and global competitiveness.
- ·
economictimes.indiatimes.com
India's CDMO industry set for global shift as pharma diversifies beyond China: Sai Life Sciences
Indian contract manufacturers are poised for significant growth as global pharmaceutical giants diversify away from China. Companies like Sai Life Sciences are investing heavily…